user avatar
Naval Daver, M.D.
@Daver_Leukemia
Interests: #AML , #MDS, #Immunotherapy, #FLT3, #TP53 . Faculty at @LeukemiaMDA. Clinical research, education. Dad of three. Tweets are mine.
Houston, TX
faculty.mdanderson.org/Naval_Daver/De…
Joined December 2014
5,618
Following
6,270
Followers
Posts
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Sep 4, 2021
    Excited to get some experience with NK cell based therapies in AML. Early data looks promising. Seems like harnessing the innate immune system (NK and macrophages) may be more important for AML @MDAndersonNews @NitinJainMD @doctorpemm @AaronGoodman33 @TapKadia
    user avatar
    Lisa Palacios
    @Lisa_Palacios
    Aug 27, 2021
    Open @MDAndersonNews #ClinicalTrial Study #2021-0414 PhI Study of FT538 as Monotherapy in R/R Acute Myelogenous #Leukemia and in Combination with Monoclonal Antibodies in R/R Multiple Myeloma | PI: Naval Daver @Daver_Leukemia | NCT04614636 | mdanderson.org/patients-famil… #leusm #AML
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Apr 4, 2023
    Thank you for the opportunity @JCO_ASCO . Hopeful and excited for the 3 ongoing phase III studies with magro in frontline MDS and AML. A huge 🙏🏽 to all the patients, physicians and research teams helping make these studies a reality! @MDAndersonNews @DrHKantarjian @garciamanero
    user avatar
    Journal of Clinical Oncology
    @JCO_ASCO
    Apr 3, 2023
    🙌 Magrolimab + AZA is promising for higher-risk #MyelodysplasticSyndromes, even in the setting of TP53 mutations 👉 fal.cn/3x6n8 #JCO #MDS #mpnsm #leusm @Daver_Leukemia
    11K
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Nov 4, 2021
    A great honor to be presented Educator if the Year by PER!! Thank you so much for the recognition! Was a true surprise for me at the end of my talk at CFS 😃 @MDAndersonNews @Lisa_Palacios @philtalamo @donnashort @gotoPER
    user avatar
    donnashort
    @donnashort
    Nov 3, 2021
    Presenting the Educator of The Year to ⁦@Daver_Leukemia⁩ president of PER ⁦@philtalamo⁩ #leukemia. He has been such a valued resource to us!! #congrats! ⁦@MDAndersonNews⁩ ⁦@gotoPER⁩ @gotocfs interrupting the program in true PER fashion. Great news!
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Mar 16, 2024
    I absolutely and unequivocally support this message @Dr_AmerZeidan @Ramikomrokji @TapKadia @doctorpemm @NitinJainMD
    user avatar
    Amer Zeidan عامر زيدان
    @Dr_AmerZeidan
    Mar 16, 2024
    Dr @Daver_Leukemia & I have signed the treaty of Kyoto to end all disagreements in the field & to reconcile all the differences in classification, risk stratification & response assessment between higher risk #MDSsm & #AMLsm
    4.4K
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Mar 13, 2022
    As the lesser of two evils MUD. In reality unless his TP53 VAf is low (<1%) on a sensitive NGs the 1 year postSCT OS is about 30-35% and 2 year <20%. But 20-30% is better than <5% chance of 2yr OS with AZA+VEN in TP53m AML…so that’s my sad logic here
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Jul 17, 2022
    Always great to meet up and hang out with friends, fellow researchers and good people :-). So happy to get back to in person meetings. At the PER Heme Medical Crossfire in NYC @beatalleukemia @aditishasMD @EuniceWangMD @Ramikomrokji @MJHLifeSciences
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Sep 19, 2023
    A true honor to deliver the 2023 David Grimwade Memorial Lecture. Wonderful to see the tremendous efforts and collaboration among the UK AML community! Thank you UK AML academy and @charliecraddock for the invitation @DillonHaem @mikewdennis @pvyas_oxford .
    user avatar
    Charlie Craddock CBE
    @charliecraddock
    Sep 15, 2023
    A brilliant talk by @Daver_Leukemia at UK AML Academy. Highlighting emerging strategies to improve outcomes in AML using novel targeted therapies and their exciting potential to improve transplant outcomes. Great opportunities to build links between UK and US partners.
    5.8K
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Sep 6, 2021
    Two excellent, very practical reviews by Dr Tefferi, Gangat and team. Great reads for students, residents, fellows and treating physicians @n_gangat @doctorpemm @LeukemiaJnl rdcu.be/cxc3t rdcu.be/cxda8
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    May 17, 2021
    This is a very important manuscript showing unfortunately the poor efficacy and significant cytopenias with VEN-based regimens in blast phase MPN. We need better options here...@doctorpemm @bose_prithviraj @TapKadia
    user avatar
    Naveen Pemmaraju, MD
    @doctorpemm
    Apr 24, 2021
    👉👉👉Proud to share our group’s newest paper in post-MPN-AML field just out in @BloodAdvances & highlight the outstanding work of our MPN expert Dr Lucia Masarova | #MPNSM #leusm | ashpublications.org/bloodadvances/… | @bose_prithviraj @Daver_Leukemia @LeukemiaMDA @TapKadia #endcancer
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Dec 8, 2021
    Looking forward to seeing all the cool data coming out at ASH 2021. Lots of exciting abstracts and progress in FLT3: check out the ASH FLT3 abstracts @MDAndersonNews @Lisa_Palacios @NicholasShortMD @musayilmaz54 @TapKadia @doctorpemm @GBorthakur
    user avatar
    UT MD Anderson
    @UTMDAnderson
    Dec 7, 2021
    30% to 35% of patients with AML carry the FLT3 mutation. Although the mutation is common, it’s also more difficult to treat. Dr. Naval Daver shares advances that are changing the treatment landscape for this high-risk diagnosis fal.cn/3krJY @Daver_Leukemia #EndCancer
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Aug 5, 2021
    A CLL1 autoCART for R/R AML. CLL1 looks to be a very good target for AML. We are excited about this study for AML. We are happy to see any potential patients @DrHKantarjian @TapKadia @doctorpemm @MDAndersonNews @NitinJainMD @GBorthakur
    user avatar
    Lisa Palacios
    @Lisa_Palacios
    Aug 2, 2021
    Open @MDAndersonNews Clinical Study #2021-0007 Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid #Leukemia | PI: Naval Daver, @Daver_Leukemia | NCT04789408 | mdanderson.org/patients-famil… #ClinicalTrial #leusm #AML
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Dec 18, 2020
    Proud to see this out in Blood Cancer Discovery :-). We need all the FLT3i we can get to overcome the different mechanisms of resistance @AAlotaibi_MD @musayilmaz54 @doctorpemm @TapKadia @sanamloghavi @kanagalshamanna @Lisa_Palacios @LeukemiaMDA
    user avatar
    Blood Cancer Discovery
    @BCD_AACR
    Dec 16, 2020
    ICYMI: Patterns of Resistance Differ in Patients with AML Treated with Type I versus Type II FLT3-inhibitors. #leusm #HemOnc bit.ly/34kG5nw Related commentary: Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies. bit.ly/2WmnfYU
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Jan 28, 2022
    Not uncommon scenario! IT AraC 2/week till negative three in a row, then weekly x 4, then monthly x 12 . Would do the IT chemo even post SCT to complete full course since SCT with limited EMD protection…..
  • user avatar
    Naval Daver, M.D.
    @Daver_Leukemia
    Feb 2, 2021
    Very excited to see this out in BCD. This was a real team effort and thanks to all those who contributed @musayilmaz54 @AAlotaibi_MD @doctorpemm @TapKadia @sanamloghavi @kanagalshamanna @drsangeetmd
    user avatar
    Blood Cancer Discovery
    @BCD_AACR
    Feb 1, 2021
    Ahead of Print: Patterns of Resistance Differ in Patients with AML Treated with Type I versus Type II FLT3-inhibitors. #leusm #HemOnc @Daver_Leukemia @AAlotaibi_MD @musayilmaz @LeukemiaMDA bit.ly/2YBTDHP